Nurix Therapeutics Awarded Innovation Passport for Entry into Innovative Licensing and Access Pathway (ILAP) in the United Kingdom for NX-1607
NX-1607 is being evaluated in multiple immuno-oncology indications, including a range of solid tumor types The ILAP aims to accelerate…